Merck and Japan's Eisai said on Wednesday they will shut down a late-stage study testing an experimental combination therapy ...

Dr. Anjana Pillai explains, in an interview with CURE, that treatment for liver cancer depends heavily on stage, liver ...

Liver cancer screening uses ultrasound and AFP biomarker tests, with CT or MRI for further evaluation if abnormalities are ...

Chinese researchers have revealed a mechanism that triggers metastasis of hepatocellular carcinoma (HCC)—the most common type ...

Chinese researchers have revealed a mechanism that triggers metastasis of hepatocellular carcinoma through the production of ...

Merck and Eisai halt late-stage trial as Keytruda/Lenvima combo fails to improve survival in liver cancer. Read more here.

Patients enrolled had NET liver metastases of any grade or origin that were progressive, symptomatic, or represented a high ...

A Lisburn family is desperately bidding to give their mum her life back with lifesaving cancer treatment available in the USA ...

BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly ...

After a progression-free survival win last year raised hopes for the combo's potential in hepatocellular carcinoma, an overall survival miss brings the study to a close.

MSD, known as Merck & Co in the US and Canada, licensed rights to Lenvima in 2018 in a near-$6 billion deal aimed at developing it as a partner drug to Keytruda. The combination has been approved for ...